Clinical Evidence

Explore the groundbreaking results of the SOLVE-CRT trial, a pivotal study stopped early for success at the pre-specified interim analysis. This trial demonstrated safety and effectiveness of the WiSE System in patients indicated for CRT who were previously untreatable or considered high risk upgrades.

JAMA Cardiology publishes EBR’s pivotal SOLVE-CRT study

The SOLVE-CRT trial evaluated patients indicated for CRT who were previously untreatable or considered high risk upgrades. The study found that the WiSE System, the only leadless left ventricular endocardial pacing (LVEP) device, can safely deliver CRT.

  • 16.4% improvement in left ventricular end systolic volume (LVESV), in heart failure patients in the first 6-months.
  • 80.9% of patients had no serious procedure or device-related complications in the first 6-months.

2022 Meta-analysis

A 2022 meta-analysis by Wijesuriya et al. consolidated findings from five pivotal studies conducted between 2014 and 2021. These studies collectively analyzed the outcomes of 175 HF patients who underwent the WiSE System implantation. Key findings include:

Improved echocardiographic response:

Average improvement in LVEF of 6.3% between baseline and 6-month follow-up across all 5 studies.

Improved NYHA classification:

Mean reduction of New York Heart Association (NYHA) class of 4.3 points.

Improved clinical response:

The pooled clinical response rate was 68% between baseline and 6-month follow-up.

High implant and procedural success:

Implant success rate was 96.6% with four studies reporting biventricular capture at six months in 90.6% of patients.

Limitations:

Non-randomized patients, small number of studies, heterogeneity of inclusions criteria, and a short follow-up duration of six months.

Conclusions and future directions:

Efficacy of leadless left ventricular endocardial pacing with the WiSE System was shown, supporting its use as a second-line therapy in patients in whom standard CRT has failed or is not possible.

*Wijesuriya N, Elliott MK, Mehta V, et al.Leadless left ventricular endocardial pacing for cardiac resynchronization therapy: A systematic review and meta-analysis. Heart Rhythm2022;19(7):1176-1183. DOI: 10.1016/j.hrthm.2022.02.018.

WiSE Clinical Program

Studies demonstrate on-going clinical impact of WiSE System, the leadless left ventricular endocardial pacing (LVEP) solution.

WiSE-CRT
SELECT-LV
Post-Market Surveillance Registry
SOLVE-CRT
Study Design
Single-arm, safety and feasibility
Single-arm, safety and efficacy
Real-world safety and performance
Single-arm, Roll-in
Pivotal: randomized and single-arm
# of Patients
13
34
153
31
183
# of Sites
11
7
19
68
Regions
EU
EU
EU, UK
AU, EU, UK, US

Publications

Clinical Study References